Becton Dickinson and (BDX) Price Target Lowered to $280.00 at Raymond James

Becton Dickinson and (NYSE:BDX) had its price objective decreased by Raymond James from $290.00 to $280.00 in a research note released on Tuesday. Raymond James currently has a strong-buy rating on the medical instruments supplier’s stock.

A number of other brokerages have also recently issued reports on BDX. UBS Group started coverage on Becton Dickinson and in a report on Tuesday, November 27th. They set a neutral rating and a $260.00 target price on the stock. Deutsche Bank started coverage on Becton Dickinson and in a report on Thursday, December 6th. They set a buy rating and a $280.00 target price on the stock. TheStreet cut Becton Dickinson and from a b+ rating to a c+ rating in a report on Friday, December 7th. Zacks Investment Research cut Becton Dickinson and from a buy rating to a hold rating in a report on Wednesday, February 6th. Finally, Citigroup reduced their target price on Becton Dickinson and from $279.00 to $256.00 and set a buy rating on the stock in a report on Wednesday, January 2nd. Five research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of $255.75.

Becton Dickinson and stock opened at $247.57 on Tuesday. The stock has a market capitalization of $65.83 billion, a P/E ratio of 22.49, a PEG ratio of 1.72 and a beta of 1.21. Becton Dickinson and has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The business had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the business earned $2.48 earnings per share. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. As a group, equities analysts predict that Becton Dickinson and will post 12.1 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 1.24%. The ex-dividend date is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

In other news, EVP Ribo Alberto Mas sold 4,808 shares of Becton Dickinson and stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $255.03, for a total transaction of $1,226,184.24. Following the transaction, the executive vice president now owns 22,476 shares in the company, valued at approximately $5,732,054.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vincent A. Forlenza sold 3,123 shares of Becton Dickinson and stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $796,458.69. Following the transaction, the chief executive officer now owns 215,372 shares in the company, valued at approximately $54,926,321.16. The disclosure for this sale can be found here. Insiders have sold a total of 29,684 shares of company stock worth $7,518,574 in the last quarter. 0.12% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. raised its position in Becton Dickinson and by 6.8% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 11,149 shares of the medical instruments supplier’s stock valued at $2,909,000 after buying an additional 708 shares during the last quarter. MML Investors Services LLC raised its position in Becton Dickinson and by 37.4% in the 3rd quarter. MML Investors Services LLC now owns 8,754 shares of the medical instruments supplier’s stock valued at $2,285,000 after buying an additional 2,383 shares during the last quarter. Chartwell Investment Partners LLC raised its position in Becton Dickinson and by 29.3% in the 3rd quarter. Chartwell Investment Partners LLC now owns 7,471 shares of the medical instruments supplier’s stock valued at $1,950,000 after buying an additional 1,691 shares during the last quarter. FTB Advisors Inc. raised its position in Becton Dickinson and by 29.3% in the 3rd quarter. FTB Advisors Inc. now owns 4,892 shares of the medical instruments supplier’s stock valued at $1,277,000 after buying an additional 1,108 shares during the last quarter. Finally, Artemis Investment Management LLP raised its position in Becton Dickinson and by 2,601.2% in the 3rd quarter. Artemis Investment Management LLP now owns 50,108 shares of the medical instruments supplier’s stock valued at $13,073,000 after buying an additional 48,253 shares during the last quarter. Institutional investors and hedge funds own 85.32% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Net Income

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.